Adjuvant Nivolumab Plus Ipilimumab vs Nivolumab Alone in Patients With Resected Stage IIIB–D/IV Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
J. Clin. Oncol 2022 Sep 26;[EPub Ahead of Print], JS Weber, D Schadendorf, M Del Vecchio, J Larkin, V Atkinson, M Schenker, J Pigozzo, H Gogas, S Dalle, N Meyer, PA Ascierto, S Sandhu, T Eigentler, R Gutzmer, JC Hassel, C Robert, MS Carlino, AM Di Giacomo, MO Butler, E Muñoz-Couselo, MP Brown, P Rutkowski, A Haydon, JJ Grob, J Schachter, P Queirolo, L de la Cruz-Merino, A van der Westhuizen, AM Menzies, S Re, T Bas, V de Pril, J Braverman, DJ Tenney, H Tang, GV LongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.